Taisho Pharmaceutical Launches Lusefi – A Newly Approved Oral Anti-Diabetic Drug For Type 2 Diabetes

dsc_6009Lusefi®, an oral anti-diabetic for type 2 diabetes mellitus which has just been launched by Taisho Pharmaceutical is expected to provide adequate glycaemic control, which lowers blood glucose and serve as a new alternative prescription.

It is an orally-active second generation sodium-glucose cotransporter 2 (SGLT2) inhibitor that is developed and produced by Taisho Pharmaceutical Japan. Formulated with a unique new mechanism of action that selectively inhibits SGLT2 – this treatment lowers blood glucose levels by inhibiting the reabsorption of glucose in the renal tubule, thus increasing urinary glucose excretion and eventually reducing blood glucose levels. Ideal for type 2 diabetes mellitus patients aged 20 and above.

A clinical study on Lusefi® that was conducted in Japan demonstrated excellent improvement in the blood glucose level for both monotherapy and in combination with six types of of oral antidiabetic drugs. The glucose level was sutained for up to 52 weeks. At the end of the study, it was found that in addition to lowering and maintaining a healthy blood glucose level, the anti glycaemic effect of Lusefi® also helped patients decrease their Body Mass Index (BMI) score. Throughout the study, Lusefi® also demonstrated excellent safety profile.

Lusefi® with its active ingredients of Luseogliflozin Hydrate is available in 2.5mg and 5mg tablets via doctors’ prescription.

Dr Zanariah Hussein, Consultant Endrocrinologist at Hospital Putrajaya and Dr Chan Siew Pheng, Consultant Endrocrinologist at Subang Jaya Medical Centre were also present at the media launch event to discuss the rising prevalence of Type 2 Diabetes in Malaysia as well as the research that has been conducted in the field of diabetes.

Juniper

City slicker, prolific blogger and food lover who loves to review products and food & everything else in between.

Related Posts

LG Malaysia Puts Effortless Home Living In Focus With Its Latest Line-Up Of Smart Life Solutions

Mr Justin Choi (second from right), Managing Director of LG Electronics Malaysia, together with Mr Hobin Jun (second from left), Product Director of LG Subscription Business; Ms Hoo Wai Sam…

CERRUTI 1881 Ushers In ‘A New Chapter’ With Refreshed IOI City Mall Kiosk And FW26 Watch Collection

From left to right: Billy Lim, Brand Director of A.D. Time Sdn. Bhd.; Kwan Junyi, Business Development Director of A.D. Time Sdn. Bhd.; M.B. Lim, Executive Business Director of A.D.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Le Méridien Putrajaya Celebrates Dual Honours At HAPA® Awards 2026

  • By Juniper
  • November 17, 2026
  • 3 views
Le Méridien Putrajaya Celebrates Dual Honours At HAPA® Awards 2026

BookXcess @ 118 Mall Brings A Malaysian Neighbourhood To Life

  • By Juniper
  • November 16, 2026
  • 5 views
BookXcess @ 118 Mall Brings A Malaysian Neighbourhood To Life

Hakka Cuisine At Its Best: Hakkayu Sunway Pyramid

  • By Juniper
  • November 15, 2026
  • 11 views
Hakka Cuisine At Its Best: Hakkayu Sunway Pyramid

LG Malaysia Puts Effortless Home Living In Focus With Its Latest Line-Up Of Smart Life Solutions

  • By Juniper
  • November 13, 2026
  • 12 views
LG Malaysia Puts Effortless Home Living In Focus With Its Latest Line-Up Of Smart Life Solutions

MRCA Branding Education Charity Foundation Launches Prestigious “MRCA Foundation Iconic Brands” To Celebrate Business Excellence And Drive Charitable Impact

  • By Juniper
  • November 13, 2026
  • 12 views
MRCA Branding Education Charity Foundation Launches Prestigious “MRCA Foundation Iconic Brands” To Celebrate Business Excellence And Drive Charitable Impact

Bayer Calls For Urgent Action On Chronic Disease As Asia Pacific Faces Rapid Ageing

  • By Juniper
  • November 12, 2026
  • 18 views
Bayer Calls For Urgent Action On Chronic Disease As Asia Pacific Faces Rapid Ageing